EU delays approval of Novavax’s revised COVID vaccine, FT reports

EU regulators have delayed a decision to approve Novavax’s variant-tailored COVID-19 vaccine, in a setback for the biotech which is battling a slump in demand for coronavirus jabs, Financial Times’ Donato Paolo Mancini reports. The European Medicines Agency, which was due to approve the updated jab last Friday, instead requested more information. The regulator had also raised questions to the drugmaker in 2021 for its first COVID vaccine before eventually approving the shot, the author notes.